HCPCS Level II drug code
J7608 — Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
In short
J7608 is the HCPCS Level II code for acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram. CMS assigns NDCs for Acetylcysteine to it. The Medicare Part B payment limit is $6.398 per unit (October 1, 2026 through December 31, 2026).
Code
CMS HCPCS file- Descriptor
- Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
- Short descriptor
- Acetylcysteine non-comp unit
- Code set
- HCPCS Level II, maintained by CMS
- Effective
- Jan 1, 2008
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the units to build the claim line.
NDCs billed under J7608
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 17 NDCs to J7608 for Acetylcysteine. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Acetylcysteine | 00409-3307-03 | Pfizer Inc | 3 × 30 | 9 |
| Acetylcysteine | 00409-3308-03 | Pfizer Inc | 3 × 30 | 18 |
| Acetylcysteine | 00517-7504-25 | American Regent, Inc. | 25 × 4 | 10 |
| Acetylcysteine | 00517-7604-25 | American Regent, Inc. | 25 × 4 | 20 |
| Acetylcysteine | 42494-0435-25 | Cameron Pharmaceuticals, LLC | 25 × 4 | 10 |
| Acetylcysteine | 42494-0436-25 | Cameron Pharmaceuticals, LLC | 25 × 4 | 20 |
| Acetylcysteine | 63323-0690-30 | FreseniUS Kabi USA, LLC | 3 × 30 | 18 |
| Acetylcysteine | 63323-0690-44 | FreseniUS Kabi USA, LLC | 3 × 30 | 18 |
| Acetylcysteine | 63323-0691-30 | FreseniUS Kabi USA, LLC | 3 × 30 | 9 |
| Acetylcysteine | 63323-0692-10 | FreseniUS Kabi USA, LLC | 3 × 10 | 6 |
| Acetylcysteine | 63323-0693-10 | FreseniUS Kabi USA, LLC | 3 × 10 | 3 |
| Acetylcysteine | 63323-0694-04 | FreseniUS Kabi USA, LLC | 25 × 4 | 20 |
| Acetylcysteine | 63323-0694-44 | FreseniUS Kabi USA, LLC | 25 × 4 | 20 |
| Acetylcysteine | 63323-0695-04 | FreseniUS Kabi USA, LLC | 25 × 4 | 10 |
| Acetylcysteine | 70069-0018-25 | Somerset Pharma, LLC | 25 × 4 | 10 |
| Acetylcysteine | 70069-0019-25 | Somerset Pharma, LLC | 25 × 4 | 20 |
| Acetylcysteine | 70069-0020-03 | Somerset Pharma, LLC | 3 × 30 | 18 |
J7608: common questions
- Is J7608 a CPT code?
- No. J7608 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J7608?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 17 NDCs under J7608, for Acetylcysteine. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J7608?
- $6.398 per 1 gm, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.